1,3-ditolylguanidine has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Andrés, L; Estrada Valencia, M; Herrera-Arozamena, C; Laurini, E; Morales-García, JA; Pérez, C; Pérez-Castillo, A; Pricl, S; Ramos, E; Rodríguez-Franco, MI; Romero, A; Viña, D; Yáñez, M | 1 |
| Faull, RL; Jansen, KL; Leslie, RA; Storey, P | 1 |
2 other study(ies) available for 1,3-ditolylguanidine and Alzheimer Disease
| Article | Year |
|---|---|
Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Donepezil; Enzyme Inhibitors; Flavonoids; Humans; Indans; Lipoxygenase Inhibitors; Male; Mice, Inbred BALB C; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurogenesis; Neuroprotective Agents; Piperidines; Receptors, sigma; Sigma-1 Receptor | 2018 |
Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss.
Topics: Aged; Alzheimer Disease; Autoradiography; Binding Sites; Cell Death; Female; Guanidines; Hippocampus; Humans; Male; Receptors, sigma; Reference Values; Tissue Distribution | 1993 |